AbbVie Buys Apogee
AbbVie is acquiring Apogee Therapeutics, a biotech company developing an experimental eczema drug, for $10.9 billion.
Apogee Therapeutics is developing a promising atopic dermatitis drug.
AbbVie is acquiring Apogee Therapeutics, a biotech company developing an experimental eczema drug, for $10.9 billion.
Apogee Therapeutics is developing a promising atopic dermatitis drug.